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Abstract
Recent studies demonstrate that lithium and valproic acid (VPA), two commonly used
mood-stabilizing drugs, have neuroprotective effects against a variety of insults.
Inhibition of the pro-apoptotic enzyme, glycogen synthase kinase-3P (GSK-3P), was
suggested to be the mechanism of action of neuroprotection for both drugs. In this study,
we tested if lithium and VPA could protect cultured cerebellar granule neurons (CGNs)
from GSK-3P-mediated apoptosis induced by trophic withdrawal (serum/potassium
deprivation). Lithium concentration-dependently (1-20 mM) protected CGNs. Indirubin,
a specific, direct GSK-3P inhibitor, was also neuroprotective. On the contrary, VPA (1-
20 mM) did not provide any neuroprotection and even potentiated cell death. Immunoblot
analysis revealed that lithium inhibited the trophic deprivation-induced activation of
GSK-3P as well as the in vivo phosphorylation ofTau on Serl99, an exclusive target site
for GSK-3p. Quite the opposite, VPA did neither inhibit GSK-3P activation nor hinder
GSK-3p-mediated Tau phosphorylation. Besides GSK-3P activation, induction of the c-
Jun stress response is also essential for apoptosis initiation in trophic deprived CGNs.
Therefore we examined the effects of lithium and VPA on c-Jun expression following
serum/potassium withdrawal. In accordance with the neuronal survival, lithium prevented
the high increase in c-Jun expression, whereas VPA further elevated it. Altogether, our
results show that VPA, unlike the common belief, is not a GSK-3 inhibitor and does not
provide neuroprotection against GSK-3P -mediated apoptosis.
Introduction
1. Serum and potassium withdrawal of cerebellar granule neurons
During the development of the central nervous system, approximately halfof the neurons
will undergo apoptosis due to limited amounts of extracellular trophic support, to ensure
the formation of a physiologically relevant neuronal network. This death is an important
part of the process by which appropriate connections are made between neurons and their
targets. This type of cell death (apoptosis) can be mimicked by an in vitro system, by
using cultured rat cerebellar granule neurons (CGNs) incubated with serum-free and low
potassium (5mM) medium. The death of developing neurons in this model has the classic
morphological and biochemical characteristics of apoptosis. In addition, mature neurons
will undergo apoptosis in response to exogenous toxic stimuli. Such stimuli can be
responsible for neurodegenerative diseases. This model system gives us a useful tool to
investigate the molecular mechanism ofboth cell death and the protection from cell death
for some specific diseases.
1.1 Inactivation of PI 3-kinase/PKB survival signaling pathway
Recent studies have established a key role for phosphatidylinositol 3-kinase (PI 3-
kinase)/protein kinase B (PKB) signaling pathway in regulating trophic factor-dependent
neuronal survival. This pathway is essential for neurotrophins rescue of cerebellar
granule neurons following serum and potassium withdrawal, and oxidative stress (1). The
neurotrophins are a family of structurally related molecules including nerve growth factor
(NGF), insulin-like growth factor- 1 (IGF-1), and brain-derived neurotrophic factor
(BDNF). Under the stimulation of neurotrophins which act through the Trk family of
receptor tyrosine kinases, PI 3 -kinase phosphorylates the membrane phospholipid PIP2 to
form PIP3, leading to the activation of serine/threonine kinase Akt, also known as PKB.
Akt/PKB then phosphorylates a number of substrates and modulates the activity of
downstream target proteins, which influences multiple cellular functions such as
glycogen synthesis, gene expression, and cell survival. One substrate for Akt is Bad, a
pro-apototic member that belongs to the Bcl-2 family. Bad induces cell death by
stimulating the release of cytochrome c from mitochondria. Phosphorylation of Bad by
Akt creates a binding site for proteins that sequester Bad in the cytosol, thereby
preventing the translocation of Bad to the mitochondrial membrane, thus enhancing the
cell survival. Akt may also directly block caspase activation by phosphorylating caspase-
9.
In addition to these direct effects on components of the cell death machinery, Akt can
regulate GSK-3P activity. Under basal conditions, GSK-3P is constitutively active,
phosphorylating and inhibiting glycogen synthase. Once Akt is activated, it
phosphorylates GSK-3 P on Ser9 and inhibits GSK-3P activity, thus the repression of
glycogen synthase is alleviated and glycogen synthesis is favored. The importance of this
regulatory action of Akt has gained recognition as multifunctional effects of GSK-3P
have been identified on regulating transcription factors, cytoskeletal proteins, and the
involvement of cellular events such as embryonic patterning and cell apoptosis.
Withdrawal of the depolarizing reagent potassium and certain growth factors contained in
serum will lead to inactivation of PI-3 kinase and reduced PKB activity; the chronic
depolarization induced by this high concentration of
K+ is thought to imitate endogenous
excitatory activity, and low
K+
will potentially decrease the intracellular
Ca2+
concentration, which induces apoptosis partially through the suppression of PI3-K
activity (2). In turn, the repression on glycogen synthase kinase-3p (GSK-3P) by PKB is
relieved and causes dephosphorylation of GSK-3p on Ser9 and hyperactivation.
Expression of a dominant-negative (loss of function) mutant of GSK-3P or addition of
selective GSK-3 P inhibitors can protect CGNs from serum/potassium deprivation-
induced apoptosis, suggesting the pro-apoptotic role of GSK-3P in the PI-3 K/PKB
pathway negatively regulating neuronal survival (3,4).
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Fig 1. The PI 3-kinase signaling pathway and cell survival. Survival factors such as
NGF activate receptor protein-tyrosine kinases, leading to activation of PI 3-kinase and
formation of PIP3. PIP3 recruits the protein kinase Akt to the plasma membrane where it
is activated as a result of phosphorylation by PDK. Akt then appears to phosphorylate a
number of proteins that contribute to cell survival. The targets of Akt that have been
implicated in suppression of apoptosis include the Bcl-2 family member Bad, caspase-9,
several transcription factors, and the protein kinase GSK-3, which affects cell metabolism
and protein synthesis (5).
1.2 Activation of stress-associated JNK/c-Jun pathway
Another important cellular event involved in trophic withdrawal-induced cell death is the
activation of stress-associated c-Jun N-terminal kinase (JNK) activity, which results in c-
Jun protein expression, phosphorylation, and potentiation of c-Jun transcriptional activity.
Transcriptionally active c-Jun is a pivotal trigger of apoptosis after neurotoxic insults
such as excitotoxicity occurring during ischemia and epilepsy, in response to axotomy
and upon withdrawal of trophic support. The activation of c-Jun leads to consequent
induction of Bim (a proapoptotic BH3-only Bcl-2 family member), Bax-dependent
cytochrome C release into the cytoplasm, caspase activation and cell death (6). Bcl-2
family proteins are important regulators of cytochrome c release. Bcl-2, Bcl-x and Bcl-w
are able to suppress apoptosis, whereas Bax is a pro-apoptotic protein that induces cell
death. Bcl-2 family members form homo-and heterodimers. The balance between the
relative levels of anti- and pro-apoptotic proteins determines cell fate towards death or
survival. The anti-apoptotic Bcl-2 family proteins bind to the mitochondrial membrane,
whereas Bax in its active form can induce the release of cytochrome c, resulting in the
formation of the apoptosome complex consisting of Apaf-1, caspase 9 and ATP (7).
Expression of a c-Jun dominant-negative mutant, which cannot be phosphorylated and
activated, prevents the death of cerebellar granule neurons following survival signal
withdrawal, whereas overexpression of c-Jun induces apoptosis in granule neurons (8). A
recent report suggests that GSK-3p may facilitate the downstream events of c-Jun
induction, Bim expression and subsequent apoptosis, acting with JNK to coordinate the
execution of c-Jun stress response and neuronal death (9).
NGF withdrawal
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Figure 2. Hypothetical model
showing how c-Jun, Bim, and
cytochrome c are connected in
the dell death pathway in neurons
(10).
2. A multifunctional kinase GSK-3P
Glycogen synthase kinase-3p (GSK-3P), originally identified as the enzyme capable of
phosphorylating and inactivating the enzyme glycogen synthase, is a serine/threonine
protein kinase ubiquitously expressed in all eukaryotes. GSK-3P is a key regulator and
downstream negative effecter of numerous signaling pathways, including
phosphotidylinositol 3-kinase (PI-3k)/protein kinase B (PKB) pathway and Wingless
(Wnt) pathway. GSK-3 P is involved in a wide range of cellular processes, such as
glycogen metabolism, embryonic patterning, cell proliferation, axonal remodeling, and
cell apoptosis. Disregulation of GSK-3p activity in the adult brain has been linked to
neuropathology in neurodegenerative diseases such as Alzheimer's disease and certain
psychiatric disease. The research on the influence of GSK-3 P on neuronal function is
tremendous valuable and searching for drugs targeting GSK-3 p can be beneficial in
exploring the mechanism ofhow GSK-3P regulates diverse cellular processes.
2.1 Two GSK-3 isoforms
There are two mammalian GSK-3 isoforms encoded by distinct genes: GSK-3oc (51kDa)
and GSK-3P (47kDa). The difference in size is due to a glycine-rich extension at the N-
terminus ofGSK-3a. These two isoforms share 98% identitywithin their kinase domains
(11). Homologues ofGSK-3 in all eukaryotes examined to date display a high degree of
homology. Isoforms from species as distant as flies and humans display > 90% sequence
similarity within the kinase domain (12). GSK-3a and GSK-3P, although structurally
similar, are not functionally identical.
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Fig. 3. Schematic representation ofmammalian GSK-3a and GSK-3p. Sites of serine
and tyrosine phosphorylation are indicated with blue arrowheads. The glycine-rich N-
terminal domain unique to GSK-3cc and the conserved kinase domain shared by both
isoforms are highlighted (13).
2.2 GSK-3P structure and kinase activity
As the crystal structure shows, GSK-3p has the typical two-domain kinase fold with a P-
strand domain (residues 25-138) at the N-terminal end and an cc-helical domain at the C-
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terminal end (residues 139-343) The ATP-binding site is at the interface of the a-helical
and P-strand domain and is bordered by the glycine-rich loop and the hinge. The
activation loop (residues 200-226) runs along the surface of the substrate-binding groove
(14). GSK-3 has a preference for cellular substrates that are primarily phosphorylated,
which greatly increases the efficiency of GSK-3p phosphorylation by 100 to 1,000 fold
(15). The consensus sequence for GSK-3 substrates is Ser/Thr-X-X-X-Ser/Thr-p, where
the first Ser or Thr is the target residue, X is any amino acid, and the last Ser-p or Thr-p is
the site ofpriming phosphorylation (13).
Fig 4. Structure of GSK3p. GSK3p
has two-domain kinase fold with a P-
strand domain (residues 25-138) at the
N-terminal end and an a-helical
domain at the C-terminal end (residues
139-343) The ATP-binding site is at
the interface of the a-helical and P-
strand domain and is bordered by the
^k ! glycine-rich loop and the hinge. The
\J ACTIVATION activation loop (residues 200-226) runs
^pS" ^ LOOP
along the surface of the substrate-
binding groove. GSK3p has two
285 phosphorylation sites that influence its
catalytic activity. Phosphorylation of
Ser9 causes inactivativation ofGSK3.
Phosphorylation of Tyr 216, increases
its catalytic activity (14).
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2.3 GSK-3P phosphorylation and inactivation
Although GSK-3a/p is a constitutively active protein kinase in the resting cell, it is
subjected to regulation by numerous enzymes through serine phosphorylation on Ser21 of
GSK-3a and Ser9 of GSK-3p. Phosphorylation of Ser9/Ser21 creates a primed pseudo-
substrate that binds intramolecularly to the positively charged pocket and occupies the
catalytic site, acting as a competitive inhibitor for true substrate (13).
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Fig 5. Regulation of GSK-3P activity by serine phosphorylation. Both unprimed
substrates and substrates phosphorylated by a priming kinase (PK) are capable of being
phosphorylated by the active GSK-3p. The priming phospho-residue at position N + 4,
binds a pocket of positive charge arising from the arginine (R) and lysine (K) residues
indicated. This directs a serine or threonine at position N to the active catalytic site
(C.S.). When an inactivating kinase (IK) such as PKB/Akt phosphorylates GSK-3P on
serine 9 (S9), the phosphorylated N terminus becomes a primed pseudo-substrate that
occupies the positive binding pocket and active site of the enzyme, acting as a
competitive inhibitor for true substrates. This prevents phosphorylation of any substrates
(13).
2.4 The role ofGSK-3P in PI-3K pathway
As illustrated at the beginning, GSK-3p is negatively regulated by protein kinase B
through phosphorylation on Ser9. If PKB activity is repressed under certain conditions,
such as serum deprivation or potassium withdrawal, GSK-3p can be dephosphorylated,
indicating its hyperactivation.
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2.5 The role ofGSK-3P in Wnt pathway
The Wnt signaling pathway, named for its most upstream ligands, the Wnts, has been
demonstrated to play important roles in controlling embryonic patterning, cell fate, cell
proliferation, and differentiation. Its role in cell development has been probed in fruit
flies, nematodes, zebra fish, frogs, and mice. Many of the known Wnt loss-of-function
mutations have been generated in the mouse and some highly intriguing phenotypes are
seen. For example, inactivation of Wnt-7a results in animals with dorsal-ventral polarity
limbs (16). Similarly, the phenotype of Wnt-4 mutations causes kidney defects (17).
Members of the Wnt family interact with trans-membrane receptors of the Frizzled
family. The binding of Wnt by the Frizzled protein causes the Frizzled protein to activate
the Disheveled protein. Once the Disheveled protein is activated, it inhibits the activity of
GSK-3p. If GSK-3P was active, it would phosphorylate the N-terminal domain of P-
catenin, thereby targeting it for ubiquitylation and proteosomal degradation. However,
when the Wnt signal is given and GSK-3P is inhibited, P-catenin is dephosphorylated,
accumulated in the cytosol and then translocated into the nucleus. Once inside the
nucleus, it can form a heterodimer with an LEF/TCF DNA-binding protein, becoming a
transcription factor. This complex binds to and activates the Wnt-responsive genes (18).
Mutations in p-catenin that prevent its phosphorylation by GSK-3p have been found in
cancers of the skin, colon, prostate, liver, endometrium and ovary (19).
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Fig 6. The Wingless pathway Wingless (Wnt) polypeptides bind to cell surface
receptors of the Frizzled family. Signaling from Frizzled leads to inhibition of the
protein kinase GSK-3, resulting in stabilization of /^catenin and an increase in the
concentration of /?-catenin in the cytosol. Free /^catenin then forms a complex with
the transcription factor LEF1 and the /?-catenin/LEFl complex translocates to the
nucleus and drives gene expression (13).
2.6 GSK-3P and axonal remodeling
As the above illustrates, Wnt factors regulate cell fate decisions in early development.
Moreover, WNTs also play important roles later in the development of the central
nervous system by regulating the axonal cytoskeleton and the clustering of synaptic
proteins at nerve terminals (20, 21). WNT-7a can increase the growth cone size and
axonal spreading along the axon in developing neurons. In addition, WNT-7a increases
the clustering and level of synapsin I, a presynaptic protein involved in synapse formation
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and function (22, 23). Also, lithium, a direct GSK-3P inhibitor, can mimic the effect of
Wnt-7a on the axonal remodeling and synaptic protein clustering. This suggests that
GSK-3p may play an important role in axonal remodeling and presynaptic differentiation
(20).
2.7 Other GSK-3P substrates
GSK-3P phosphorylates numerous proteins including transcription factors, translation
factor and other proteins involved in cytoskeletal regulation, intracellular vesicular
transport, cell cycle progression, circadian rhythm regulation and apoptosis.
Phosphorylation of these substrates by GSK-3p is most often inhibitory, as in the case of
glycogen synthase, P-catenin (13). Microtubule-associated protein (MAP) tau, the
structural protein that promotes tubulin polymerization and stabilizes microtubules, is a
well-established physiological substrate of GSK-3p. Hyperphosphorylated tau is the
primary component of neurofibillary tangles (NFTs), which is one of the
neuropathological hallmarks of Alzheimer's disease. Tau phosphorylation involves
numerous kinases, such as GSK-3P, cyclin-dependent kinase 5(Cdk5), P38 kinase, and c-
Jun N-terminal kinase (JNK). Among the abnormal phosphorylation sites identified,
GSK-3P specifically phosphorylates serine 199, 202, 235, 396, 404 and 413, and
threonines 205 and 231 (24).
2.8 GSK-3P and Alzheimer's disease
Alzheimer's disease (AD), the most common neurodegenerative disease, is characterized
by progressive memory loss and impairments in language and behavior that ultimately
13
lead to death. The cognitive decline in AD is accompanied by neuronal atrophy and loss,
mainly in the cortex, hippocampus and amygdala. In addition to a specific pattern of
neuronal cell death, AD is characterized by two neuropathlogical hallmarks, senile
plaques and neurofibrillary tangles (NFTs). Senile plaques are extracellular deposits of
amyloid fibrils composed of the 39^3 amino acid P-amyloid peptide (AP) often
surrounded by dystrophic neuritis. NFTs are intraneuronally generated aggregates of
paired helical filaments (PHFs), which are assembled from the hyperphosphorylated form
of tau (25).
GSK-3p has been linked to many of the major neuropathological mechanisms that are
associated with Alzheimer's disease. GSK-3P was found to be identical to tau protein
kinase I (TPK I), an enzyme that was identified in brain extracts due to its ability to
phosphorylate tau in vitro. GSK-3P is one of the best candidates for generating the
hyperphosphorylated tau. It has been shown to phosphorylate tau in most sites that are
found in PHFs, both in transfected cells and in vivo. Furthermore, GSK-3P accumulates
in the cytoplasm of pretangle neurons, and its distribution in the brains staged for AD
neurofibrillary changes is coincident with the sequence of development of these changes
(25).
It is reported that GSK-3P phosphorylates the amyloid precursor protein (APP). The
exposure of cultured cortical and hippocampal primary neurons to neurotoxic P-amyloid
(AP) derived from cleavage of the APP can induce activation of GSK-3P (26), tau
hyperphosphorylation (27) and cell death (27, 28). Blockade of GSK-3P expression or
activity, either by antisense oligonucleotides or by lithium (a direct GSK-3p inhibitor),
prevents Ap- induced neurodegeneration of cortical and hippocampal primary cultures
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(28, 29). Furthermore, transgenic mice conditionally over-expressing GSK-3P display
hyperphosphorylated tau and some signs ofneuronal degeneration (25).
In addition, GSK-3P interacts with presenilin proteins, encoded by the genes (PS-1 and
PS-2) that are responsible for triggering inherited forms of AD (familial AD). Several
investigators recently reported that presenilin 1 binds to GSK-3P (30), and facilitates the
co-localization of GSK-3P and tau (thus facilitating GSK-3P-mediated phosphorylation
of tau). Presenilin 1 also binds to other substrates of GSK-3P such as P-catenin, and the
amyloid precursor protein (APP), acting as a scaffold for bringing GSK-3P into close
proximity with these substrates, which have critical roles in AD and cell
survival/apoptotic mechanisms.
2.9 GSK-3p and bipolar disorder
Bipolar disorder (BPD) is characterized by an alternating pattern of emotional highs
(mania) and lows (depression), and associated with significant morbidity and mortality,
affecting about 1% of the population worldwide. Severe mood alteration affects one's
sense of well being, as well as self-esteem, judgment, attention, motivation, learning and
memory, sleep, appetite, and overall psychomotor activity. Mood disorders have
traditionally been conceptualized as neurochemical disorders of certain neurotransmitter
systems such as serotonergic, adrenergic, and glutamatergic and GABAergic systems.
However, recent brain imaging and morphometric-postmortem studies demonstrate
regional changes in CNS volume, as well as changes in the number and/or size of glia
and neurons in discrete brain areas of patients with mood disorders. These data suggest
neurotrophic function, cellular growth, death, and resilience as possible factors that
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contribute to these disorders (31). Patients respond remarkably well to mood-stabilizing
drugs, such as lithium and the anticonvulsant VPA, in spite of their totally different
chemical structures. Although the biochemical basis for mood-stabilizer therapies to BPD
remains poorly understood, several recent reviews have addressed the possible
mechanism of action of lithium and VPA. As lithium is a direct GSK-3P inhibitor, and
VPA was reported to inhibit GSK-3P as well, it is an intriguing point that disregulation of
GSK-3P may have an influence on this psychiatric disorder.
3. The effects of lithium and VPA on regulating GSK-3P
3.1 Lithium
Lithium has been used for BPD since the late 1940s, and it is an effective treatment for
both acute and long-term phases of BPD, as well as adjunctive prophylaxis in unipolar
recurrent depression. Side effects of lithium treatment include diabetes insipidus,
subclinical hypothyroidism, hyperparathyroidism, and benign neurophilia. Unfortunately,
lithium has a narrow therapeutic window and is effective in only 60-80% ofBPD patients
(32).
Two protein families have been demonstrated as direct cellular targets of lithium and are
affected at concentrations used clinically (33). One is the super-family of structurally
related phosphomonoesterases, including EVIPase, IPP, fructose-1,6-biphosphatase, and
the rat PAP phosphatase (RnPIP). Biochemical studies show that the magnesium ion-
binding site located in the active site of the enzymes is the target of lithium. Lithium
prevents product release and traps products in the active site, resulting in an
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uncompetitive inhibition (34). The other target is the family of serine/threonine protein
kinases that GSK-3p belongs to. Enzyme kinetic experiments suggest that this inhibition
is also through competition for magnesium ion binding. The fact that lithium inhibits both
of these two enzyme groups through an interaction with magnesium suggests that this
may be a general mechanism of lithium action (33).
Lithium inhibits GSK-3P (Ki = 1 - 2mM) in an uncompetitive mode in vitro (35) and it
also inhibits GSK-3P in vivo. Therefore, the various effects of lithium on metabolic,
developmental, and neuronal morphology and survival could be explained by its action
on GSK-3p.
3.1.1 Molecular changes in lithium treatment
It has been reported that lithium affects neurotransmitter release, metabolism of biogenic
monoamines, and neuronal signal transmission through perturbation of the distribution of
various cations, including sodium, magnesium, and calcium (32). Lithium can regulate a
number of phosphoproteins at the level of expression and/or phosphorylation, including
neurofilament proteins (36), microtubule-associated proteins (MAPs) (20), and protein
kinase C (PKC) substrates (37).
3.1.2 Neuroprotection of Lithium
Lithium protects neurons from a variety ofpro-apoptotic stimuli in vitro and in vivo (32).
For example, treatment with lithium for seven days protects cultured rat cerebellar,
cerebral cortical, and hippocampal neurons against glutamate-induced excitotoxicity (38).
Lithium also protects cultured cerebellar granule neurons against C2-ceramide (39), p-
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amyloid induced neurodegeneration (29), potassium deprivation and serum withdrawal
(4). Pretreatment of mice with lithium delays radiation-induced apoptosis in external
cerebellar granule cells (40).
Lithium inhibits tau phophorylation through inhibition ofGSK-3P, as shown in vitro and
in vivo. Therefore, lithium has been considered as a potential therapy for
neurodegenerative diseases in which hyperphosphorylation of tau is a principal
pathological feature (32).
3.2 Valproic acid (VPA)
The effectiveness of VPA as an anticonvulsant was discovered serendipitously when
other compounds were dissolved in VPA for administration to animals used in
experimental models of epilepsy (32). Since then, VPA has been widely used in both
generalized and partial epilepsies. VPA was used as a mood stabilizer nearly 35 years
ago, and it is effective in acute mania and as prophylaxis for recurrent mania and
depression. The side effects of VPA include hepatotoxicity, teratogenicity, and
suppression of bone marrow function. Administration of VPA in pregnant women
increases the risk of a number of congenital anomalies, such as spina bifida aperta
(defects in posterior neural tube closure), congenital heart defects, cleft palate, and limb
defects.
3.2.1. Molecular changes in VPA treatment
Although the direct target of VPA has not been identified definitively, it has been
reported that VPA increases the level of y-aminobutyric acid (GABA); inhibits sodium,
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potassium, and calcium channel function; inhibits histone deacetylases (HDACs); And, in
common with lithium, VPA activates the mitogen-activated protein kinase (MAPK)
pathway; increases expression ofBcl-2, and activates AP-1 -dependent transcription.
Initially, VPA was reported to directly inhibit GSK-3p activity (41), but this is not
supported by a number of further experiments. Some suggested that VPA treatment could
lead to an indirect change in GSK-3 activity (42). Others reported that VPA could
regulate GSK-3P phosphorylation via activation ofprotein kinase B (PKB), the upstream
enzyme phosphorylating and inactivating GSK-3P (43).
3.2.2. Neuroprotection ofVPA
VPA protects cultured rat hippocampal neurons against P-amyloid and glutamate-induced
injury (44). VPA also prevents cultured cerebellar granule cells from apoptosis induced
by low potassium (3). However, Mora et al. reported that inhibition ofPI-3K activity by
LY294002 (a specific PI-3K inhibitor) blocks the protection afforded by VPA against
apoptosis, whereas lithium can still exert its protection while LY294002 is present. This
suggests that VPA protects CGNs against low-K+-induced apoptosis through PI-3K
pathway, while the protection by
Li+
is independent of this pathway (45).
Also, Hall et al. compared the effect of therapeutic concentrations of lithium (1-2 mM)
and VPA (ImM) during neuronal maturation. They showed that VPA and lithium induce
clustering of synapsin I and induce similar changes in the morphology of axons by
increasing growth cone size, spreading, and branching. More importantly, both of them
decrease the phosphorylation level of microtubule-associated protein-IB (MAP-IB is a
GSK-3P substrate) in developing neurons (42). As in vitro kinase assays shows, lithium
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partially inhibits GSK-3 p activity, while VPA does not inhibit GSK-3p. This finding also
supports the idea that both mood stabilizers inhibit GSK-3p activity through different
mechanisms: lithium directly inhibits GSK-3P; on the other hand, VPA inhibits GSK-3P
indirectly by an as-yet-unknown pathway.
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Hypothesis
From the above, we have known that GSK-3P plays a pro-apoptotic role in neuronal cell
death, and selective GSK-3P inhibitor such as lithium can protect neurons from many
apoptotic insults. In order to understand better how GSK-3p exerts its neurotoxic effect
in cell death, and the mechanism of how VPA and lithium regulate GSK-3p activity and
promote cell survival, we wish to test the ability of lithium and valproic acid to protect
neurons from the pro-apoptotic effects of serum/potassium withdrawal. We planned to
use cultured rat cerebellar granule neurons (CGNs) switched to serum-free and low
potassium (5mM) medium. The reason for selecting this cell type is that they are
abundant and the in vitro culture is homogeneous. Moreover, the death of developing
neurons in this model has the classic morphological and biochemical characteristics of
apoptosis. The following specific aims are proposed:
1) Analysis of neuroprotection by lithium and VPA. This aim is to investigate
whether lithium and VPA could prevent trophic-deprivation induced neuronal apoptosis.
Briefly, CGNs will be treated with serum free and low potassium medium in absence or
presence of lithium or VPA, or other inhibitors ofGSK-3p (Indirubin is used as a positive
control). After 24h incubation, the neuronal survival will be evaluated by performing
MTT assays. If both lithium and VPA are neuroprotective in this model system, the cell
viability in lithium- or VPA-treated CGNs is expected to be higher than that in
serum-
free and
low-K+
treated CGNs.
2) Mechanism of neuroprotection by lithium or VPA. In this aim, we will investigate
whether protection ofCGNs by lithium or VPA involve inhibition ofGSK-3p activity by
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regulatory phosphorylation at Ser9 of GSK-3P molecules (Aim 2A), and alteration in
GSK-3P-specific phosphorylation of tau (Aim 2B). Briefly, CGNs will be treated as
outlined in Aim 1 for defined time intervals such as 2h; 6h and immunoblots will be
performed using phospho-GSK-3P-specific (Ser9) and phospho-tau-specific (Serl99)
antiserum. Here the phosphorylation status of tau will be used as an indicator ofGSK-3p
activity. If these two drugs could indeed regulate GSK-3p activity, they will either inhibit
GSK-3P activation by Ser9 phosphorylation, or reduce GSK-3 P enzyme activity.
3) The effects of lithium or VPA on c-Jun protein expression In this aim, we will
examine whether neuroprotection ofCGNs by lithium or VPA involve inhibition of c-Jun
protein expression (Aim 3). CGNs will be treated as described in Aim2. Immunoblots
will be performed using c-Jun antiserum. If both of the drugs are neuroprotective, we
speculate that c-Jun protein expression should be depressed, or at least, should not be
elevated.
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Materials and Methods
Materials
Basal medium Eagle, heat-inactivated fetal calf serum and gentamicin were purchased
from Gibco BRL, Invitrogen Corporation (Grand Island, NY). The culture plates were the
products of Sarstedt (Newton, NC) and Corning (Corning, NY). Lithium chloride,
valproic acid sodium salt (sodium valproate), indirubin-3'-monoxime, poly-L-lysine,
trypsin, DNase, cytosine-P-arabinofuranoside and soybean trypsin inhibitor were from
Sigma-Aldrich (St. Louis, MO, USA). Rabbit polyclonal antibodies against phospho-
GSKa/p(Ser21/9), phospho-(Serl99)-Tau and c-Jun (N) were obtained from Cell
Signaling Technology (Beverly, MA), Sigma-Aldrich and Santa Cruz Biotechnology
(Santa Cruz, CA), respectively. The mouse anti-GSK-3a/p and the rabbit anti-Tau (H-
150) antibodies were from Santa Cruz Biotechnology. The horseradish peroxidase-
conjugated donkey anti-rabbit IgG and sheep anti-mouse IgG were from Amersham
Pharmacia Biotech (Amersham Place, UK).
Cerebellar granule cell cultures
Primary cultures of cerebellar granule cells were prepared from 7-8-day-old Sprague-
Dawley rat cerebella (Charles River) as previously described (46) with some
modifications (47). Briefly, cerebelli were dissected and meninges and blood vessels
removed. Then cerebelli were minced using a single edged razor blade with two passes at
90 to each other at approximately 0.5 mm intervals. Minced tissue was incubated in
0.25% trypsin solution at 37 C for 12 min, cells were dispersed by trituration in a
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DNase- and soybean trypsin inhibitor-containing solution (0.01% and 0.05%,
respectively) and plated onto 24-well plates
(5xl05
cells/ml/well), 12-well plates
(106
cells/2 ml/well) or 6-well plates
(2xl06
cells/4 ml/well) coated with 10 pg/ml of poly-L-
lysine. Cells were cultured for 6-8 days at 37 C in an atmosphere of 5% C02/95% air in
Basal Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 25 mM
KC1, 2 mM glutamine, and 100 pg/ml gentamicin (K25+S). Cytosine-P-
arabinofuranoside (Ara-C; 10 uM) was added 24 h after plating to limit the number of
nonneuronal cells to less than 5%.
Assessment ofcell viability
The MTT assay was used to assess the viability of neurons. It has been widely assumed
that mitochondrial dehydrogenases in living cells convert soluble MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] into an insoluble blue formazan
product that can be dissolved in isopropanol and the color intensity measured
spectrophotometrically. In this way, MTT assay would assess the integrity of
mitochondria characteristic of viable cells. However, recent findings suggest that MTT is
taken into cells through endocytosis and reduced primarily in the endosome/lysosome
compartment instead of the mitochondria. Nevertheless, the MTT assay, as a measure of
cell viability, is still valid because it measures endocytosis, a fundamental feature ofmost
living cells.
The MTT assay was initiated by removing the culture medium and adding MTT (0.3
mg/ml) dissolved in Basal Eagle's medium supplemented with 25 mM KC1, 2 mM
glutamine, and 100 pg/ml gentamicin. Following 1 h incubation at
37 C, the medium
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was aspirated and 0.3 ml of isopropanol was added to lyse the cells and dissolve the
formazan crystals. Aliquots (100 pi) of this solution were pipetted into 96-well
microplates and the absorbance was recorded at 570 nm (with background subtraction at
630 nm) in a microplate reader. Cell viability was expressed as a percentage of the
absorption in control cultures (=100 %).
Trophicfactor withdrawal
Trophic factor withdrawal was carried out on the 6th-7th days in vitro. Cultures were
washed twice either with K25-S (Basal Eagle's medium supplemented with 25 mM KC1,
2 mM glutamine, and 100 ug/ml gentamicin) or K5-S (Basal Eagle's medium
supplemented with 2 mM glutamine, and 100 ug/ml gentamicin), then the corresponding
medium (K25+S or K5-S) was added to the cells for the indicated time periods.
Immunoblotting
frnmunoblot analysis was performed as described previously (47). After removing the
culture medium, the cells were lysed in ice-cold lysis buffer (50 mm Tris, pH 7.5, 0.1%
Triton X-100, 2 mm EDTA, 2 mm EGTA, 1 pm microcystin, 1 mm Na3V04, 50 mm
NaF, 10 mm sodium P-glycerophosphate, 5 mm sodium pyrophosphate, 0.1% (v/v) P-
mercaptoethanol and 1 tablet/50 mL of complete protease inhibitor cocktail). After
centrifugation at 15,000 g for lOmin, cell lysates containing equal amounts of total
protein were fractionated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and electrophoretically transferred to the Hybond ECL
nitrocellulose membrane (Amersham). The filters were blocked for 1 h with 5% skimmed
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milk in IX Tris-buffered saline, 0.5% Tween-20, followed by a 1-h incubation with the
primary antibody diluted in the same blocking solution. The antibodies against GSK-
3a/p, Tau and c-Jun were used in 1:500 dilution, whereas the anti-phospho-GSK-3a/p
(Ser21/9)) and
anti-phosphoTau199
antibodies were applied at 1:1000 dilution. After
having detected the phospho-GSK-3a/p or phospho-Tau199levels, the nitrocellulose
membranes were stripped using the Restore Western Blot Stripping Buffer from Pierce,
and the corresponding membranes were reprobed for total GSK-3 and total Tau,
respectively. Equal loading and uniformity of the protein transfer to the nitrocellulose
membrane were also verified by the equal intensity of unspecific bands on the films
following the enhanced chemiluminescence reaction.
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Results
Lithium, but not VPA can protect cultured CGNs against cell death induced by
trophic withdrawal
Primary cultures of cerebellar granule neurons were maintained in medium containing
serum (10%) and 25 mM KC1 as survival factors. Serum and potassium deprivation
triggers GSK-3P-mediated apoptosis in these cultures (4, 9, 48). To investigate the effects
of lithium and VPA on neuronal survival in this culture model, on the
6-71
day in vitro,
serum and potassium were withdrawn (K5-S) in the presence of increasing concentrations
of either lithium chloride or valproic acid sodium salt (sodium valproate) for 24 hours.
Cell viability was measured by the MTT assay. Consistent with previous findings, more
than 60% of the neurons died after 24 hours. As expected, lithium (1-20 mM) provided
concentration-dependent neuroprotection (Fig IB). The specific, direct GSK-3P inhibitor,
indirubin-3'-monoxime (indirubin), also protected CGNs against trophic deprivation,
providing complete neuroprotection at a concentration of 10 uM. On the contrary, VPA
(1-20 mM) was not neuroprotective at all and even potentiated cell death at lower
concentrations (see Fig IB). In addition to the water-soluble sodium valproate, we also
treated our cultures with pure valproic acid (dissolved in DMSO), but this preparation
was neither neuroprotective (data not shown).
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Figure 1A. Microscopic view of cerebellar granule neurons (CGNs) after 24-hour
incubation with different chemicals in K5-S medium. K25+S: CGNs can be maintained
in medium containing serum and 25 mM K+. K5-S: Serum and
K+ deprivation triggers
cell death, representing characteristic morphology of apoptosis, including shrinking of the
cytoplasm, plasma membrane blebbing, and loss of dendrites. K5-S + Li: Lithium can
protect CGNs against cell death. K5-S + VPA: VPA treatment cannot prevent cell death.
K5-S + Indirubin: Indirubin can provide complete neuroprotection. Final drug
concentrations: [LiCI] = 15 mM, [Indirubin] = 10 uM, [VPA] = 15 mM.
Figure IB. Lithium, but not VPA can protect cultured CGNs against cell death induced
by trophic withdrawal. After 24 hours of serum and potassium withdrawal, more than
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60% of the CGNs died. Lithium is protective at therapeutic concentration (ImM) and
demonstrates neuroprotection in a dose-dependent manner. Indirubin, a direct GSK-3B
inhibitor, promotes CGN survival significantly. In contrast, VPA cannot prevent CGNs
from death, and cell viability is even lower than that in K5-S. Columns and bars represent
meanS.E.M. of 3-6 separate experiments with 3-6 different culture preparations.
Statistical significances were determined by one-way ANOVA followed by Bonferroni's
test for multiple comparisons.
Lithium, but not VPA, can inhibit GSK-3P activation followed by trophic
withdrawal
Trophic withdrawal in cultured CGNs causes the blockade of the PI3-K/PKB survival-
signaling pathway leading to GSK-3 activation as a result of decreased inhibitory
phosphorylation ofGSK-3a and GSK-3P on Ser21 and Ser9, respectively (4, 9, 48, 49).
To test whether lithium and VPA can inhibit GSK-3 activation, immunoblot experiments
were performed using antibodies against phospho-GSK-3a/p(Ser21/9) and GSK-3a/p to
detect the levels of inactive (phosphorylated) GSK-3 and total GSK-3, respectively.
Serum and potassium were withdrawn from DIV 6 CGN cultures for 2h or 6 h, in the
presence or absence of either 10 mM lithium chloride or 10 mM sodium valproate. The
level of phospho-GSK-3, especially of phospho-GSK-3p, significantly decreased after 2
h and remained also low after 6 h, indicative of a rapid and prolonged GSK-3 activation
(see Fig 2.). Lithium not only prevented GSK-3 dephosphorylation but even increased the
phospho-GSK-3 level above the control (K25+S). Moreover, if lithium was added to the
cultures after the first two hours of serum/potassium deprivation, it was able to induce
inhibitory phosphorylation of GSK-3 (Fig. 2). These facts imply that lithium, besides
inhibiting phosphatases, activates some kinase(s) phosphorylating GSK-3. VPA,
however, not only did not inhibit GSK-3 dephosphorylation, but even potentiated it
considerably further increasing the proportion of active GSK-3 (see Fig. 2).
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Figure 2. CGN cultures were maintained in medium containing serum (S) and 25 mM
KC1 (K25+S). Serum/potassium (K5-S) deprivation in the absence or in the presence of
LiCI (10 mM), VPA (10 mM) or indirubin (10 uM) was carried out on DIV 6-7, for the
indicated time periods. At the end of the treatments, cells were lysed and the cell lysates
were immunoblotted with an antibody to phospho-GSK-3a/p(Ser21/9) to detect the level
of inactive (phosphorylated) GSK-3. The nitrocellulose membrane was then stripped and
reprobed with an antibody to total GSK-3a/p. Phospho-GSK-3p band intensities were
determined by densitometry and normalized to the corresponding total GSK-3p band
intensities. Fold changes of the normalized phospho-GSK-3P band intensities are
represented as ratios to the control normalized phospho-GSK-3P band intensity (K25+S).
Immunoblots representative of similar results obtained in 3 separate experiments with 3
different culture preparations are shown.
Lithium, but not VPA, can inhibit GSK-3P-mediated tau phosphorylation
Although, VPA did not prevent the trophic deprivation induced activation of GSK-3P in
CGNs, it may affect the enzymatic activity of GSK-3p. The microtublule-associated
protein Tau is a well-known in vivo GSK-3p substrate (50-54). GSK-3P has been
reported to phosphorylate multiple sites on Tau but these sites can also be phosphorylated
by other kinases (24, 55-57). The serine 199 of Tau, however, is exclusively
phosphorylated by GSK-3p (24, 51-53). To test if VPA has any effect on GSK-3p
enzymatic activity in vivo, we examined Tau phosphorylation on Serl99 following 2 h of
serum/potassium withdrawal in DIV 6 CGN cultures. The level of phospho-Serl99-Tau
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was detected by immunoblot using a specific anti-phospho-Serl99-Tau antibody.
Following serum/potassium withdrawal for 2 hours, Tau became hyperphosphorylated on
Serl99 as a biochemical consequence of high GSK-3p activity (see Fig. 3, lane 2). Both
lithium and indirubin, which are direct GSK-3p inhibitors, prevented Tau
phosphorylation on Serl99 (Fig. 3, lanes 3 and 5). VPA, however, did not inhibit GSK-
3P-mediated phosphoryaltion ofTau on Serl99 (Fig. 3, lane 3).
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Figure 3. Cerebellar granule neuron cultures were maintained in medium containing
serum (S) and 25 mM KC1 (K25+S). Serum/potassium (K5-S) deprivation in the absence
or in the presence of LiCI (10 mM), VPA (10 mM) or indirubin (10 pM) was carried out
on DIV 6-7, for 2 h. At the end of the treatments, cells were lysed and the cell lysates
were immunoblotted with antibodies tophospho-Tau199to assess the enzymatic activity
ofGSK-3P in vivo (serine 199 ofTau is specifically phosphorylated by GSK-3P (24, 51-
53). The nitrocellulose membrane was then stripped and reprobed with an antibody to
total Tau. Immunoblots representative of similar results obtained in 3 separate
experiments with 3 different culture preparations are shown.
Lithium can decrease c-Jun induction, whereas VPA induces c-Jun protein
expression
Besides GSK-3 activation, induction of the c-Jun stress response is also essential for
apoptosis initiation in trophic deprived CGNs (8, 58). A recent study demonstrated that
GSK-3 inhibitors prevent the c-Jun induction following trophic withdrawal in CGNs (9).
Therefore, we examined the effects of lithium and VPA on c-Jun expression following
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serum/potassium withdrawal. Trophic deprivation induced a massive, prolonged
elevation of the c-Jun protein level (Fig. 4, lanes 2 and 6). In accordance with the
neuronal survival (see Fig. 1), both lithium and indirubin prevented the high increase in
c-Jun expression, whereas VPA further elevated it (Fig. 4).
K5-S 2 h K5-S 6 h
K25+S - Li+ VPA Indi - Li+ VPA Indi
+- c-Jun
Figure 4. CGN cultures were maintained in medium containing serum (S) and 25 mM
KC1 (K25+S). Serum/potassium (K5-S) deprivation in the absence or in the presence of
LiCI (10 mM), VPA (10 mM) or indirubin (10 pM) was carried out on DIV 6-7, for the
indicated time periods. At the end of the treatments, cells were lysed and the cell lysates
were immunoblotted with an antibody to c-Jun. An immunoblot representative of similar
results obtained in 3 separate experiments with 3 different culture preparations is shown.
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Discussion
Valproic acid is a widely prescribed antiepileptic drug and is being used increasingly in
the treatment of bipolar disorder, especially in the United States. Like other
anticonvulsants, VPA inhibits sodium, potassium and calcium channel function, although
its direct in vivo target has not been identified definitely (33). Since the report by Chen et
al. (41), describing VPA as a GSK-3 inhibitor in a human neuroblastoma cell line, SH-
SY5Y, VPA is regarded as a neuronal GSK inhibitor. This firm belief has been surviving
despite the findings by Phiel et al. (59), showing that VPA does not inhibit GSK-3 in
Neuro2A cells. This study also demonstrated that the increased level of P-catenin in VPA
treated cells, instead of being a result of GSK-3 inhibition (preventing P-catenin
phosphorylation and subsequent degradation) is due to histone deacetylase (HDAC)
inhibition by VPA. It should be noted that the elevation of P-catenin levels after 1-6 days
ofVPA treatment in SH-SY5Y cells was the strongest argument for the in vivo GSK-3
inhibitory effect ofVPA in the above-mentioned report by Chen et al. (4). Our results in
the present study clearly show that, contrary to well-established GSK-3 inhibitors, such
as lithium and indirubin, VPA does not inhibit GSK-3 in cerebellar granule neurons, and
does not protect against GSK-3-mediated neurotoxicity either. The neuroprotective effect
of VPA observed in different experimental paradigms (60-63) is, therefore, most likely
the result of its HDAC inhibitory and/or ion channel blocking actions. It was recently
shown, e.g., that VPA prolongs the life span of cortical neurons in culture and this
neuroprotection is associated with inhibition of HDAC (63a). The same group showed
later that in brains of VPA-treated mice 33 genes were up-regulated and 44 genes were
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downregulated (63b). These genes could be broadly classified into several functional
groups involved in apoptosis, cell growth, cell cycle, cell adhesion, signal transduction,
development, protein biosynthesis, receptor activity, metabolism and transport. An
upregulated gene of interest was heat shock protein 70 (HSP 70) since HSP 70 has been
shown to have a neuroprotective role (64).
Primary cultures of cerebellar granule neurons (CGNs) can be maintained in medium
containing serum (10%) and 25 mM KC1 as survival factors. The chronic depolarization
induced by this high concentration of potassium is thought to imitate endogenous
excitatory activity. Serum and potassium deprivation triggers GSK-3-mediated apoptosis
in these cultures (4, 9, 48). In agreement with our results, Mora et al. (48) also found that
VPA was not protective against combined serum and potassium deprivation in cultured
CGNs. In contrast to this, in a study by Li et al. (3), VPA provided neuroprotection in
serum/potassium deprived CGN cultures. In this study, however, extremely high cell
densities (3-4-fold of the usual ones) were used, and serum and potassium withdrawal for
24 h only resulted in 22% cell death, contrary to the typical 50-70% neuronal death
detected in other studies (48, 65-67) including our present report (see Fig. IB). The
higher cell density inevitable means the presence ofmuch more glial cells, making CGN
cultures considerably more resistant to trophic deprivation (68). The mechanism how
VPA protected against the slight toxicity in those dense CGN cultures (3), therefore, is
not clear.
Besides GSK-3 activation, induction of the c-Jun stress response is also essential for
apoptosis initiation in trophic deprived CGNs (8, 58). A recent study by Hongisto et al.
(9) demonstrated the cooperative action of the c-Jun activator kinase, c-Jun N-terminal
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kinase, and GSK-3 in regulating the c-Jun stress response in CGNs. Structurally
independent inhibitors of GSK-3, such as lithium, indirubin and FRAT1 (the GSK-3 -
binding inhibitory protein), prevented the serum/potassium deprivation-induced c-Jun
protein increase and subsequent neuronal apoptosis (9). Our results confirm these
findings. VPA in our experiments, instead of inhibiting, further potentiated the c-Jun
induction, which can give grounds for its deteriorative effect in trophic deprivation.
Although, both lithium and VPA have been shown to induce c-Jun expression and to
enhance AP-1 mediated gene expression in cell lines and neurons (69-73), only lithium
was reported to have an opposite, reducing effect on stress-induced c-Jun responses (9,
75-77).
In summary, our results demonstrate that VPA is not a GSK-3 inhibitor in neurons, and
call the attention, that VPA, instead of being neuroprotective, can even exacerbate
neuronal death upon trophic deprivation by potentiating the c-Jun stress response.
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